Rosiglitazone improves insulin sensitivity with increased serum leptin levels in patients with type 2 diabetes mellitus
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Rosiglitazone (RSG) is known to be an agonist for the peroxisome proliferator-activated receptor-gamma (PPARgamma) and promotes differentiation of pre-adipocytes into adipocytes. Leptin is highly correlated with adiposity, while the activation of PPARgamma is known to inhibit Lep gene expression and leptin release. This study was performed to evaluate the relationship between changes in circulating leptin levels, insulin sensitivity and regional adiposity after RSG treatment. Two hundred fifty-one type 2 diabetic patients (176 men and 75 women) who had been treated with sulfonylurea and/or metformin received 4 mg of RSG daily, in addition to the previous medications. Before and after RSG treatment (average duration 5.6+/-0.9 months), indices of insulin resistance, metabolic parameters, and serum leptin and adiponectin levels were measured. Abdominal subcutaneous fat thickness (SFT(max)) and visceral fat thickness were measured by sonography. After RSG treatment, HOMA-IR index decreased significantly (2.82+/-1.94 vs. 2.01+/-1.58), while BMI and SFT(max) increased, and leptin (4.72+/-3.77 vs. 5.69+/-4.30 ng/ml) and adiponectin levels (7.54+/-10.20 vs. 12.89+/-10.13 microg/ml) increased. The increase in serum leptin correlated with an increase in SFT(max) (r=0.511, p<0.001) and with a reduction in HOMA-IR (r=-0.368, p<0.001). The correlation of Delta leptin with Delta HOMA-IR and with Delta SFT(max) was higher in females and among insulin-resistant subjects. In conclusion, RSG improves the insulin sensitivity with increased serum leptin levels in patients with type 2 diabetes mellitus, which is related to an increase in subcutaneous adiposity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Pajvani, U. B., Hawkins, M., Combs, T. P., Rajala, M. W., Doebber, T., Berger, J. P., Wagner, J. A., Wu, M., Knopps, A., Xiang, A. H., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m311113200 · Cited by 1,163
Requirement for LIml in head-organizer function
Shawlot, W., & Behringer, R. R. (1995) · Nature · doi:10.1038/374425a0 · Cited by 805
Kim, Y. M., Cha, B. S., Kim, D. J., Choi, S. H., Kim, S. K., Ahn, C. W., Lim, S.-K., Kim, K. R., Huh, K. B., & Lee, H. C. (2005) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2004.05.001 · Cited by 43
Self-citation
Cited by
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
Salpeter, S. R., Greyber, E., Pasternak, G. A., & Salpeter (posthumous), E. E. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002967.pub4 · Cited by 893
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
Salpeter, S. R., Greyber, E., Pasternak, G. A., & Salpeter (posthumous), E. E. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002967.pub3 · Cited by 434
Thomas, M. K., Nikooienejad, A., Bray, R., Cui, X., Wilson, J., Duffin, K., Milicevic, Z., Haupt, A., & Robins, D. A. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa863 · Cited by 345
“Increases in circulating levels of adiponectin, an adipokine implicated in the regulation of both glucose and lipid metabolism, have been associated with multiple interventions that increase insulin sensitivity (9-12).”
BackgroundGurusinghe, D., Gill, S., Almario, R. U., Lee, J., Horn, W. F., Keim, N. L., Kim, K., & Karakas, S. E. (2010) · Fertility and Sterility · doi:10.1016/j.fertnstert.2009.03.017 · Cited by 8
“It is conceivable that changes in leptin may account for the differential effects of insulin sensitizers on androgens: TZD treatment, which suppresses androgen levels, increases leptin, whereas metformin, which does not affect androgen levels, has no effect on leptin (29, 30).”
BackgroundSelf-citation
Metadata
- Authors
- Kim, H. J., Kim, S. K., Shim, W. S., Lee, J. H., Hur, K. Y., Kang, E. S., Ahn, C. W., Lim, S. K., Lee, H. C., & Cha, B. S.
- Venue
- Diabetes Research and Clinical Practice
- Publisher
- Elsevier BV
- Published
- 2008-07
- Volume
- 81
- Issue
- 1
- Pages
- 42-49
- ISSN
- 0168-8227 (ISSN-L)
- OpenAlex
- W2121982863
- Cited by
- 35
- References
- 4
- FWCI
- 1.86
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rosiglitazone improves insulin sensitivity with increased serum leptin levels in patients with type 2 diabetes mellitus. https://app.cochat.ai/papers/10.1016/j.diabres.2008.02.001
- The paper
- Kim, H. J., Kim, S. K., Shim, W. S., Lee, J. H., Hur, K. Y., Kang, E. S., Ahn, C. W., Lim, S. K., Lee, H. C., & Cha, B. S. (2008). Rosiglitazone improves insulin sensitivity with increased serum leptin levels in patients with type 2 diabetes mellitus. Diabetes Research and Clinical Practice. https://doi.org/10.1016/j.diabres.2008.02.001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.